* subjects who have a record of hiv or aids * subject has a serious chronic disease * active bleeding or ongoing clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment * pregnant or lactating females * subjects with liver cirrhosis whose child-pugh score is b or c * subjects who have liver disease abnormalities with alt or ast \> 5 times uln * estimated glomerular filtration rate (egfr) \< 30 ml/min (including patients receiving hemodialysis or hemofiltration) * qtcb or qtcf \>500ms * subjects who have clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) in medical history * subjects with rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator's opinion * subjects who are not appropriate for the study, as the investigator's opinion * subjects who have hypersensitivity to the investigational drug * subjects participated in any other clinical trial (including drugs for the treatment of covid-19) 3 months prior to screening

* subjects who have a record of hiv or aids * subject has a serious chronic disease * active bleeding or ongoing clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment * pregnant or lactating females * subjects with liver cirrhosis whose child-pugh score is b or c * subjects who have liver disease abnormalities with alt or ast \> 5 times uln * estimated glomerular filtration rate (egfr) \< 30 ml/min (including patients receiving hemodialysis or hemofiltration) * qtcb or qtcf \>500ms * subjects who have clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) in medical history * subjects with rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator's opinion * subjects who are not appropriate for the study, as the investigator's opinion * subjects who have hypersensitivity to the investigational drug * subjects participated in any other clinical trial (including drugs for the treatment of covid-19) 3 months prior to screening

- subjects who have a record of hiv or aids - subject has a serious chronic disease - active bleeding or ongoing clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment - pregnant or lactating females - subjects with liver cirrhosis whose child-pugh score is b or c - subjects who have liver disease abnormalities with alt or ast > 5 times uln - estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration) - qtcb or qtcf >500ms - subjects who have clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) in medical history - subjects with rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator's opinion - subjects who are not appropriate for the study, as the investigator's opinion - subjects who have hypersensitivity to the investigational drug - subjects participated in any other clinical trial (including drugs for the treatment of covid-19) 3 months prior to screening

- subjects who have a record of hiv or aids - subject has a serious chronic disease - active bleeding or ongoing clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment - pregnant or lactating females - subjects with liver cirrhosis whose child-pugh score is b or c - subjects who have liver disease abnormalities with alt or ast > 5 times uln - estimated glomerular filtration rate (egfr) < 30 ml/min (including patients receiving hemodialysis or hemofiltration) - qtcb or qtcf >500ms - subjects who have clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) in medical history - subjects with rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator's opinion - subjects who are not appropriate for the study, as the investigator's opinion - subjects who have hypersensitivity to the investigational drug - subjects participated in any other clinical trial (including drugs for the treatment of covid-19) 3 months prior to screening